

FRONTIERS IN CLINICAL DRUG RESEARCH - **DEMENTIA**



Editor:
Atta-ur-Rahman, FRS

Bentham Books

Frontiers in Clinical Drug Research - Dementia

(Volume 1)

Edited by

Prof. Atta-ur-Rahman, *FRS*

Kings College, University of Cambridge, Cambridge, UK

Highly Effective Teaching / Fgo gvk

Volume # 1

Editor: Atta-ur-Rahman, *FRS*

ISBN (Online): 978-981-14-1094-9

ISBN (Hardback/Hardcover): 978-981-14-1093-2

© 2020, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 MEETING THE CHALLENGES OF FALLS AND HIP FRACTURES IN PEOPLE WITH ALZHEIMER'S DISEASE	1
<i>Kareeann Sok Fun Khow and Tuck Yean Yong</i>	
INTRODUCTION	2
RISK FACTORS FOR FALLS IN ALZHEIMER'S DISEASE	2
COMMON RISK FACTORS FOR ALZHEIMER'S DISEASE AND HIP FRACTURES	4
HIP FRACTURE AND COGNITIVE DECLINE	6
PREVENTING AND MANAGING HIP FRACTURES IN ALZHEIMER'S DISEASE	6
PRIMARY PREVENTION OF FALLS AND HIP FRACTURES	7
Falls Prevention	7
Managing and Preventing Osteoporosis	8
ACUTE TREATMENT OF HIP FRACTURES	9
Orthogeriatric Model of Care	9
Timing of Surgery	10
Prevention of Delirium	10
Adequate Analgesia	11
Early Mobilization	11
Surgery in Severe Alzheimer's Disease	11
POST-ACUTE CARE	11
Rehabilitation	12
Preventing Recurrent Falls	12
Treatment of Osteoporosis	13
Management of Depression	14
GAPS IN CURRENT EVIDENCE AND FUTURE RESEARCH	15
CONCLUSION	16
CONSENT FOR PUBLICATION	17
CONFLICT OF INTEREST	17
ACKNOWLEDGEMENTS	17
REFERENCES	17
CHAPTER 2 CHOLESTEROL IN BRAIN HEALTH AND PATHOLOGIES: THE ROLE IN ALZHEIMER'S DISEASE	26
<i>Kosara Smiljanic, Natasa Loncarevic-Vasiljkovic, Selma Kanazir and Aleksandra Mladenovic Djordjevic</i>	
INTRODUCTION	27
CHOLESTEROL IN THE BRAIN	29
Cholesterol Metabolism in the Brain	32
<i>Cholesterol Synthesis</i>	32
<i>Cholesterol Transport</i>	35
<i>Cholesterol Elimination</i>	38
CHOLESTEROL IN THE AGING BRAIN	40
Cholesterol in Brain Pathologies	40
CHOLESTEROL AND ALZHEIMER'S DISEASE	44
The Role of Apolipoprotein E in Alzheimer's Disease	46
The Role of SREB Proteins in Alzheimer's Disease	48
The Role of CYP46A1 in Alzheimer's Disease	49
The Role of Cholesterol in Tau Pathology	49

Cholesterol and APP Processing	49
The Role of Cholesterol Esters in AD Pathogenesis	51
The Role of Cholesterol-Lowering Drug Statins in Alzheimer’s Disease	51
The Impact of Dietary Restriction on Cholesterol in the Brain	53
CONCLUDING REMARKS	54
CONSENT FOR PUBLICATION	56
CONFLICT OF INTEREST	56
ACKNOWLEDGEMENTS	56
REFERENCES	56

CHAPTER 3 **ADVANCES IN TREATMENT OF MILD COGNITIVE IMPAIRMENT (MCI) AND DEMENTIA: A REVIEW OF PROMISING NON-PHARMACEUTICAL MODALITIES** 78

<i>Zahra Ayati, Dennis Chang and James Lake</i>	
PROMISING NON-PHARMACEUTICAL TREATMENTS OF MCI AND DEMENTIA ...	79
LIMITATIONS OF CONVENTIONAL MAINSTREAM TREATMENTS	79
NON-PHARMACEUTICAL TREATMENTS OF MILD COGNITIVE IMPAIRMENT [MCI] AND DEMENTIA	81
Lifestyle Changes	81
Diet	81
Exercise	83
Sleep	84
Natural Products	86
<i>Introduction</i>	86
Herbals	86
<i>Herbal Medicines used in Asian Traditional Medicine Systems</i>	86
<i>Single Herbs</i>	86
<i>Complex Herbal Formulas</i>	89
<i>Kami-untan-to</i>	91
<i>Withania somnifera (Ashwagandha)</i>	91
<i>Select Korean, Chinese and Ayurvedic Herbs</i>	92
<i>Herbals used in other Systems of Medicine</i>	92
Non-Herbal Natural Products	93
<i>Acetyl-L-Carnitine</i>	93
<i>Alpha Lipoic Acid (ALA)</i>	94
<i>Combinations of ALA and Other Nutraceuticals</i>	95
<i>Folic Acid, B-12, B-6 and Thiamine</i>	95
<i>Niacin</i>	96
<i>Vitamins C and E</i>	97
<i>DHEA and Testosterone</i>	98
<i>Estrogen</i>	99
<i>Polyunsaturated Fatty Acids [PUFA]</i>	99
<i>Phosphatidylserine and Phosphatidic Acid</i>	100
<i>CDP-choline</i>	100
<i>Essential Oils</i>	100
<i>Chelating Agents</i>	101
<i>Probiotics</i>	102
OTHER NON-PHARMACEUTICAL TREATMENT MODALITIES	103
Noninvasive Brain Stimulation	103
Music Therapy	104
Cognitive Training	104
Bright Light Exposure	105

EEG-Biofeedback	106
Sensory Stimulation Interventions	107
Massage Therapy	107
Wander Gardens	107
Mindfulness	108
Multi-Modal Interventions	108
Energetic Therapies	110
<i>Healing Touch and Therapeutic Touch</i>	110
<i>Taichi and Qigong</i>	111
CLOSING REMARKS	112
CONSENT FOR PUBLICATION	113
CONFLICT OF INTEREST	113
ACKNOWLEDGEMENTS	113
REFERENCES	113
CHAPTER 4 OVERVIEW OF ANALYTICAL METHODS IN ALZHEIMER'S DISEASE	
DRUGS: OPTICAL, CHROMATOGRAPHIC, AND ELECTROCHEMICAL METHODS	132
<i>Cem Erkmén, Burcin Bozal-Palabiyik and Bengi Uslu</i>	
INTRODUCTION	132
ANALYSIS OF APPROVED ALZHEIMER'S DISEASE DRUGS	137
Chromatographic Techniques for Analyzing Alzheimer's Disease Drugs	139
Optical Techniques for Analyzing Alzheimer's Disease Drugs	146
Electrochemical Techniques for Analyzing Alzheimer's Disease Drugs	148
ANALYSIS OF THE MAIN MOLECULAR TARGETS UNDER INVESTIGATION IN	
ALZHEIMER'S DISEASE RESEARCH	151
CONCLUSION	152
ABBREVIATIONS	152
CONSENT FOR PUBLICATION	153
CONFLICT OF INTEREST	153
ACKNOWLEDGEMENTS	153
REFERENCES	153
CHAPTER 5 TARGETING ALZHEIMER'S DISORDERS THROUGH NANOMEDICINE	165
<i>Mahima Kaushik and Dhriti Jha</i>	
INTRODUCTION	165
AD PATHOLOGY AND CURRENT TREATMENT TRENDS	167
FACTORS INFLUENCING THE TARGETING OF AD	170
TARGETING AD THROUGH NANOMEDICINE	172
DRUG DELIVERY SYSTEMS AND NANOMEDICINE	175
OUTLOOK	179
CONFLICT OF INTEREST	180
CONSENT FOR PUBLICATION	180
ACKNOWLEDGEMENTS	180
REFERENCES	180
CHAPTER 6 CURRENT CHALLENGES IN ALZHEIMER'S DISEASE	187
<i>Umar Mushtaq, Amrina Shafi and Firdous A. Khanday</i>	
INTRODUCTION	187
PATHOLOGY	188
Symptoms	193
Diagnosis	194
Therapy	195

Recent Signaling Aspect of AD	197
CONCLUSION	199
CONSENT FOR PUBLICATION	199
CONFLICT OF INTEREST	199
ACKNOWLEDGMENTS	199
REFERENCES	200
CHAPTER 7 METALS LINKED TO ALZHEIMER'S DISEASE	213
<i>Hani Nasser Abdelhamid</i>	
INTRODUCTION	213
KEY PROTEINS IN THE BRAIN	214
LINKS BETWEEN METALS AND AD	215
BIOMETALS LINK TO ALZHEIMER'S DISEASE	215
Calcium and Magnesium	215
Copper	216
Iron	217
Zinc	218
Manganese	219
Selenium	219
Non-biological Metals	219
Aluminum	219
Cadmium	220
Other Metals	220
Treatments	221
Prospective	222
CONSENT FOR PUBLICATION	224
CONFLICT OF INTEREST	224
ACKNOWLEDGEMENTS	224
REFERENCES	224
SUBJECT INDEX	458

PREFACE

The book series *Frontiers in Clinical Drug Research-Dementia* presents cutting edge reviews written by the specialists in the field. The chapters in the 1st volume focus on drug research with special emphasis on clinical trials, and research on drugs in advanced stages of development for dementia and related disorders.

Khow & Yong, in chapter 1, discuss the challenges of bone and hip fractures in patients of Alzheimer's disease. Djordjevic *et al.*, in chapter 2, discuss the role of cholesterol in brain health and pathologies with special emphasis on Alzheimer's disease. Chapter 3 by Lake *et al.* reviews the advances in the treatment of Mild Cognitive Impairment (MCI) and dementia.

Chapter 4 by Uslu *et al.* gives an overview of analytical methods for the drugs used in the treatment of this disease. Kaushik and Jha, in chapter 5, present the nanotechnological advancements for the treatment of Alzheimer's disease. Chapter 6 by Mushtaq *et al.* presents the details of current challenges in Alzheimer's disease. The last chapter by Hani Nasser Abdelhamid, summarizes recent studies on the links between metals and Alzheimer's disease.

I am grateful to all the eminent scientists for their excellent contributions. The efforts of Ms. Fariya Zulfiqar (Manager Publications) and the leadership of Mr. Mahmood Alam (Director Publications) are greatly appreciated.

Prof. Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

Aleksandra Mladenovic Djordjevic	Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
Amrina Shafi	Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir-190006, India
Bengi Uslu	Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey
Burcin Bozal-Palabiyik	Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey
Cem Erkmen	Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey
Dennis Chang	NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia
Dhriti Jha	Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India
Firdous A. Khanday	Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir-190006, India
Hani Nasser Abdelhamid	Advanced Multifunctional Materials Laboratory, Department of Chemistry, Assiut University, Assiut 71516, Egypt
James Lake	NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia
Kareeann Khaw	Aged and Extended Care Services, The Queen Elizabeth Hospital, Woodville Road, Woodville South, SA 5011, Australia Adelaide Geriatric Training Research and Aged Care Centre, University of Adelaide, Adelaide SA 5005, Australia
Kosara Smiljanic	Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
Mahima Kaushik	Cluster Innovation Centre, University of Delhi, Delhi, India
Natasa Loncarevic-Vasiljkovic	Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
Selma Kanazir	Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
Tuck Yean Yong	Internal Medicine, Flinders Private Hospital, Adelaide, South Australia, Australia
Umar Mushtaq	Department of Biotechnology, School of life Science, Central University of Kashmir, Ganderbal, Jammu and Kashmir-191201, India
Zahra Ayati	Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer's Disease

Kareeann Sok Fun Khow^{1,2,*} and Tuck Yean Yong³

¹ Aged and Extended Care Services, The Queen Elizabeth Hospital, Woodville Road, Woodville South, SA 5011, Australia

² Adelaide Geriatric Training Research and Aged Care Centre, University of Adelaide, Adelaide SA 5005, Australia

³ Internal Medicine, Flinders Private Hospital, Adelaide, South Australia, Australia

Abstract: Falls and hip fractures are common conditions among older people with Alzheimer's disease (AD) and are associated with high risk of morbidity and mortality. People with AD have up to an 8-fold increased risk of falling and 3-fold higher risk of hip fractures, compared with those who are cognitively intact. The increased risk of hip fractures among people with dementia may occur through a few pathways, including (a) risk factors that are common to both conditions, (b) the presence of dementia increasing incidence of hip fracture through intermediate risk factors such as falls and osteoporosis, and (c) side effects of treatment used in AD increasing hip fracture risk. A better understanding of these mechanisms and their effects on outcomes after hip fracture will assist in developing effective interventions and improving preventive strategies. Population aging heightens the need to recognize the interactions of these conditions in order to improve efforts to prevent hip fractures, improve outcomes through high-quality acute care and rehabilitation that returns patients to pre-morbid level of functioning, and provide evidence-based secondary prevention of falls or fragility fractures. Acute care of hip fractures focusing on orthogeriatric co-management has been shown to reduce length of hospital stay, perioperative complications including delirium, readmission rate and premature mortality. Secondary prevention of falls and further fractures is essential by ensuring risk factors for falling are addressed and osteoporosis is treated. New experimental approaches are being investigated to manage osteoporosis through surgical approaches in people with extremely high risk of recurrent hip fractures.

Keywords: Alzheimer's disease, Cognitive impairment, Dementia, Falls, Hip fracture, Orthogeriatric, Prevention, Rehabilitation, Risk factors, Treatment.

* **Corresponding author Dr Kareeann Khow:** Aged and Extended Care Services, The Queen Elizabeth Hospital, Woodville Road, Woodville South, SA 5011, Australia; Tel: +61 8 8222 8178, Fax: +61 8 8222 8593; E-mail: kareeann.khow@adelaide.edu.au

Atta-ur-Rahman (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

INTRODUCTION

Alzheimer's disease (AD) is the most frequent form of dementia in many countries. Falls and hip fractures are common interrelated problems among older people with AD. The prevalence of AD increases with age, rising from 3.0% among those aged 65 to 74 years to 18.7% among the 75 to 84 years age group and even higher at 47.2% in people over 85 years [1]. Globally, the prevalence of dementia has been doubling every 20 years and is projected to affect 81 million by 2040, with many being affected by AD [2]. AD is a progressive condition that can interfere with self-care and social functioning.

Older people are more likely to fall resulting in catastrophic and life-threatening events. In addition, falls also have adverse consequences on their quality of life and that of their families or carers. It is estimated that 28-35% of community dwelling individuals older than 65 years fall each year and more than 50% of those living in residential care facilities [3]. In the United States, the absolute number of fall-related deaths has almost tripled from 8613 in 2000 to 25819 in 2016, according to the National Vital Statistics System [4]. The same study also reported that the age-adjusted fall-related mortality rate has doubled, rising from 46.3 to 105.9 per 100,000 women and from 60.7 to 116.4 per 100,000 men [4]. Falls also impose a heavy financial cost on the healthcare system. In 2015, the total medical costs attributable to fatal and non-fatal falls in the United States was nearly \$50 billion [5].

About 85% of hip fractures happen in people over the age of 65 years [6]. With an aging population, the number of hip fractures worldwide is expected to rise from 1.7 million in 1990 to 6.3 million by 2050 [7]. In the first year after a hip fracture, only 50% regain their pre-fracture ambulation level and about 25% of people living in the community before the fracture would require care in a residential facility [8, 9]. Within three months after hip fracture, mortality is five to eight-fold higher than in age- and sex-matched controls and this excess mortality persists even after 10 years [10, 11].

This chapter will review the risk factors for falls and hip fractures in people with AD. This review will also describe the evidence for effective acute and post-acute care for hip fractures. In addition, effective strategies for primary and secondary prevention of falls and hip fractures in AD will also be examined.

RISK FACTORS FOR FALLS IN ALZHEIMER'S DISEASE

Patients with dementia including those with AD experience an eight-fold higher risk of falls compared to those without dementia, and especially for sustaining recurrent falls [12]. In one case-control study of four-year duration, 36% of

patients with AD experienced a serious fall compared to 11% among those without the condition [13]. Several risk factors for falls are more prominent among people with AD (Table 1).

Table 1. Risk factors for falls in people with Alzheimer's disease.

Changes in gait
• Shorter stride length
• Reduced gait speed
• Increased step-to-step variability
• Lower stepping frequency
• Increased double support ratio
• Increased sway path
Neurovascular instability
Delirium, especially acute hospital setting
Behavioural and psychological symptoms
Use of psychotropic medications

The ability to walk without falling depends on an intact motor, sensory, balance, postural reflexes, and vision to maintain a steady upright position and to move safely. Moreover, cognitive abilities including attention, reaction time, executive function, visuospatial skills, and navigation are important for walking safely. Studies have found that people with AD have a shorter stride length, slower gait speed, greater step-to-step variability, lower stepping frequency, increased double support ratio (more time spent in stance phase), and larger sway path than those without the condition [14 - 16]. Stride length and gait speed have been found to be associated with the risk of falls [15]. About 40% of people with AD have a gait apraxia [17]. Impaired central integration of signals for maintaining gait and balance is thought to contribute to apraxia in AD [18]. People with AD can also be impulsive and take unnecessary risks due to impaired insight and lack of perception in relation to environmental hazards [19].

AD is associated with a high prevalence of autonomic dysfunction, leading to postural hypotension [20, 21]. This may lead to falls and hip fractures. In addition, a study of participants with AD found a prevalence of carotid sinus hypersensitivity in 28% [22].

In the acute hospital setting, delirium is common among people with AD and is a major risk factor for falls [23]. Delirium persisting after hospital admission is associated with a six-fold increase in the risk of falls [24].

Cholesterol in Brain Health and Pathologies: The Role in Alzheimer's Disease

Kosara Smiljanic, Natasa Loncarevic-Vasiljkovic, Selma Kanazir and Aleksandra Mladenovic Djordjevic*

Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Belgrade, Serbia

Abstract: Cholesterol is the molecule essential for life, but also with a possible detrimental role. Apart from being a vital structural constituent of the cells, cholesterol is a factor involved in many important cell processes. However, it has been known that high blood cholesterol is associated with many pathological conditions. An elevated level of cholesterol is linked with cardiovascular disease, diabetes and neurodegenerative disorders.

Almost quarter of the total cholesterol in the body resides in the brain. This vast pool is synthesized *in situ* and it is almost completely isolated and independent from the periphery due to the presence of blood-brain barrier. In the central nervous system, cholesterol plays important role in neural cells structure and functions, including synaptic transmission. Due to this, its content must be precisely maintained in order to keep brain function well. However, cholesterol is critically challenged in the aging brain and disturbed in several of pathological conditions, like Huntington's disease (HD), Parkinson's disease (PD), Niemann-Pick type C (NPC) disease and Smith-Lemli Opitz syndrome (SLOS), traumatic brain injury, multiple sclerosis (MS) and in Alzheimer's disease (AD).

Altered cholesterol metabolism has been extensively implicated in the pathogenesis of AD. A growing amount of evidence underscores the link between disturbed intracellular trafficking of cholesterol in the brain and the formation of amyloid plaques. The inheritance of the epsilon4 allele of the Apolipoprotein E (ApoE), the main transport protein for cholesterol in the brain represents the main risk factor for late onset form of Alzheimer's disease. Other genetic polymorphisms associated with critical points in cholesterol metabolism may also contribute to the AD pathogenesis. Hypercholesterolemia has been considered nowadays also as a risk factor, and all of these players are thought to promote the production of beta-amyloid and development of AD. Additional proof towards cholesterol involvement in the pathogenesis of AD gave epidemiological data of the cholesterol-lowering drugs, statins that have been shown to decrease the risk for AD.

* **Corresponding author Aleksandra Mladenovic Djordjevic:** Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Belgrade, Serbia; Tel: +381 11 2078 338; Fax: +381 11 2761 433; E-mail: anamikos@ibiss.bg.ac.rs

This chapter is aimed to summarize existing knowledge about the brain cholesterol metabolism, how the homeostasis is changed during aging and in various neurodegenerative diseases, with special emphasis on Alzheimer's disease. As a final point, we will try to give a full insight into the environmental influences (including dietary restriction and statins therapy) on brain cholesterol homeostasis.

Keywords: Aging, Alzheimer's disease, Brain injury, Central nervous system, Cholesterol homeostasis, Cholesterol metabolism, Dietary restriction, Neurodegenerative diseases, Oxysterols, Statins.

INTRODUCTION


Nowadays, there is almost no molecule like cholesterol, surrounded by such a big debate. It has triggered so much attention since its discovery in the second half of the 18th century, and does not cease to provoke controversy among scientists, but also in the general population. It is indispensable for life in so many ways, but it can still be harmful and fatal for health. The fact that so far 13 Nobel Prizes were awarded for the achievements connected to the structure, function and metabolism of cholesterol, tells us a story about its significance. Cholesterol is often called the secret killer, but still, no cell membrane would exist without it. The cholesterol is "the one" that builds the membranes, keeps their integrity, permeability and cell viability. In contrast to a rigid cell wall that plants possess, animal cell's membranes rich in cholesterol are fluid. Its role does not stop here- cholesterol is a precursor in the biosynthesis of vitamin D, bile acids and all steroid hormones.

Representing double-edged sword cholesterol is still in the focus of a large number of studies that attempt to shed light on its role in physiological and pathological processes. French physician-chemist François Poulletier first isolated cholesterol from gallstones in 1784. It was named cholesterine by French chemist Michel E. Chevreul (Greek: chole for bile and stereos for solid). It took an entire century to get to exact molecular formula of cholesterol established by Austrian botanist Friedrich Reinitzer in 1888. Elucidating its structure was extremely difficult. Marvelous work of Heinrich O. Wieland and Adolf Windaus brought them the Nobel Prize in Chemistry in 1927 and 1928, respectively, for revealing tetracyclic cholesterol skeleton [for a review see 1]. Konrad Bloch (1964) won the Nobel Prize for the contribution to the clarification of cholesterol biosynthesis. Michael Brown and Joseph Goldstein, who received the Nobel Prize in 1985 for their work on cholesterol regulation, named cholesterol Janus, a molecule with two faces.

Every animal cell is capable of synthesizing cholesterol by a complex 37-step process and most of our cholesterol is indeed made in our own organism. However, cholesterol can be also absorbed directly from the food. The content of

cholesterol in our body is a result of a fine balance between the process of synthesis and the process of absorption. If cholesterol homeostasis is preserved, then the body compensates for any absorption of additional cholesterol by reducing cholesterol synthesis and on the contrary - it will synthesize additional cholesterol when we need it, in cases like pregnancy, or recovery from illnesses and injuries. To make things more complicated, our body recycles cholesterol whenever it is possible, rather than synthesizing it. Typically, about 50% of the cholesterol excreted by the liver is reabsorbed by the small intestine back into the bloodstream.

Cholesterol is essential for cell functioning. It is like the brick in the house wall, a structural component of each and every cell in our bodies, required for building and maintaining the integrity of animal cell membranes, thus providing a protective barrier. However, cholesterol is not only **mechanical constituent** of plasma membranes; it also **regulates the permeability and fluidity** of cell membrane over the range of temperatures. Tetracyclic ring structure (Fig. 1) provides cholesterol capability to decrease membrane fluidity and makes membrane rigid.



Cholesterol

Fig. (1). Tetracyclic ring structure of cholesterol.

Cholesterol is a compelling modulator of the membrane proteins and also participates in numerous membrane trafficking and transmembrane signaling processes [2].

Advances in Treatment of Mild Cognitive Impairment (MCI) and Dementia: A Review of Promising Non-pharmaceutical Modalities

Zahra Ayati^{1,2}, Dennis Chang² and James Lake^{2,3,*}

¹ Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

² NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia

³ Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, USA

Abstract: Currently, available mainstream approaches used to treat mild cognitive impairment (MCI) and dementia are limited. In view of the high prevalence rate of Alzheimer's disease (AD) and other forms of dementia and the enormous social and financial burden associated with dementia on a global scale, developing more effective and more cost-effective ways to treat MCI and dementia is an urgent priority. This chapter reviews research findings on promising non-pharmaceutical approaches being investigated for their potential clinical applications in treating symptoms of cognitive impairment and behavioral dysregulation associated with dementia, reducing the risk of developing dementia, and slowing rate of progression of cognitive decline in individuals with Mild Cognitive Impairment (MCI) or dementia. Non-pharmaceutical treatment approaches covered include diet, exercise, single and compound herbal formulas used in Asian medicine, herbals used in Western countries, select other natural products including dehydroepiandrosterone, idebenone, acetyl-L-carnitine, alpha lipoic acid, phosphatidylserine and phosphatidic acid, select vitamins, nPUFAs and probiotics. Other non-pharmaceutical modalities reviewed include chelating agents; non-invasive brain stimulation techniques employing weak electrical current, sound and light; music therapy; cognitive training; electroencephalography (EEG) biofeedback; multi-modal interventions; Wander gardens; sensory stimulation interventions; massage, mindfulness, and energetic therapies (Healing Touch, Therapeutic Touch, taichi and qigong). Although select natural products are supported by compelling research evidence, most modalities reviewed in this chapter are supported by limited findings. Large prospective placebo-controlled studies are needed to further elucidate mechanisms of action, verify the efficacy of the various non-pharmaceutical modalities, and identify safe and appropriate treatment protocols for MCI and dementia.

* **Corresponding author James Lake:** Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, USA; E-mail: jameslakemd@gmail.com

Atta-ur-Rahman (Ed.)

All rights reserved-© 2020 Bentham Science Publishers

Keywords: Dementia, Healing Touch and Therapeutic Touch, Lifestyle Changes, Mild Cognitive Impairment (MCI), Multi-Modal Interventions, Natural Products, Non-Pharmaceutical Treatment, Taichi and Qigong.

PROMISING NON-PHARMACEUTICAL TREATMENTS OF MCI AND DEMENTIA

- Limitations of conventional mainstream treatments
- Reviews of non-pharmaceutical treatments
 - Lifestyle changes: diet, exercise and sleep
 - Natural Products
 - Herbals
 - Herbals used in Asian systems of medicine (single herbs, complex herbal formulas)
 - Other herbals (*Rhodiola rosea*, *Melissa officinalis*, *Salvia officinalis*)
 - Non-herbal natural products: acetyl-l-carnitine, folate, B-12, B-6, thiamin, niacin, vitamin C, vitamin E, DHEA and testosterone, estrogen, n-PUFA (omega-3s), phosphatidylserine and phosphatidic acid, CDP-choline, essential oils, probiotics)
 - Other non-pharmaceutical treatment modalities
 - non-invasive brain stimulation (TMS, tDCS, gamma-band stimulation, photobiomodulation)
 - Music therapy
 - Cognitive training
 - Bright light
 - EEG biofeedback
 - Sensory stimulation interventions
 - Massage
 - Wander gardens
 - Mindfulness
 - Multi-modal interventions
 - Energetic therapies
 - Healing Touch and Therapeutic Touch
 - Taichi and Qigong

LIMITATIONS OF CONVENTIONAL MAINSTREAM TREATMENTS

A systematic review found inconclusive evidence that non-steroidal anti-inflammatory agents (NSAID), antihypertensives, cholinesterase inhibitors, hormones and other medications are effective for preventing or reducing the risk of cognitive decline during healthy aging, developing mild cognitive impairment (MCI) or reducing the risk of developing Alzheimer's disease (AD) [1]. Current mainstream treatments of AD work by inhibiting the enzyme that breaks down

acetylcholine, thus increasing available levels of the neurotransmitter that is critical for learning and memory. Although available drugs sometimes lessen the severity of cognitive decline and behavioral disturbances that accompany AD, they do not address its root causes. Only five drugs have been approved by the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease (AD) [2]. Among these the cholinesterase inhibitors include tacrine, donepezil, galantamine and rivastigmine (Alzheimer's Association. FDA-Approved Treatment for Alzheimer's) [2]. Another drug, memantine, works by antagonizing glutamate receptors and is in a class by itself. Second-generation acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are no more effective than tacrine but require less frequent dosing.

All currently available pharmaceuticals have associated side effects that can be very distressing to individuals struggling with dementia, including vomiting, diarrhea and appetite loss. Tacrine, the first cholinesterase inhibitor, was removed from the market in 2013 because of concerns over hepatotoxicity.

Other drug classes that have been investigated for possible cognitive-enhancing benefits in AD include the monoamine oxidase inhibitors (MAOIs), estrogen replacement therapy (*i.e.*, in cognitively impaired postmenopausal women), naloxone, and different neuropeptides including vasopressin and somatostatin [3]. Promising novel treatments of Alzheimer's disease currently being investigated in clinical trials include a vaccine that may immunize individuals against formation of amyloid-beta, secretase inhibitors, anti-inflammatory agents, statins and a variety of nano-medicinal approaches [4 - 6]. Findings of studies on statins in dementia are inconsistent. However, a 2017 meta-analysis of 31 studies that met inclusion criteria for size and rigor found that regular statin use is associated with significant reduction of risk of developing dementia [7].

In addition to cognitive impairment, individuals struggling with MCI and dementia frequently experience depressed mood, anxiety, and psychosis. Conventional allopathic management of complex clinical presentations uses combinations of drugs that increase risk of unsafe interactions. Behavioral disturbances, including agitation and aggressive behavior toward caregivers, are commonly encountered in demented individuals. Although cholinesterase inhibitors result in only transient improvement in the early stages of dementia, they have become the standard conventional treatment of AD and other forms of dementia in industrialized countries because of findings of reduced agitation. In addition to pharmacological management, behavioral interventions, environmental enrichment, and social support may lessen the cognitive and behavioral symptoms of dementia.

Overview of Analytical Methods in Alzheimer's Disease Drugs: Optical, Chromatographic, and Electrochemical Methods

Cem Erkmen, Burcin Bozal-Palabiyik and Bengi Uslu*

Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey

Abstract: Alzheimer's disease is a neurodegenerative disorder that results in a loss of memory, cognitive problems, and personality change. The frequency of this disease is increasing rapidly due to the aging world population. Every year, more people are exposed to this age-related disorder. It is expected that the number of individuals diagnosed with Alzheimer's disease would increase to 100 million by 2050. The treatment of Alzheimer's disease costs more than \$200 billion annually in the US and this cost will possibly grow to \$1 trillion annually by 2050. There are two categories of drugs used for the treatment of Alzheimer's disease; while the first category attempts to treat the symptoms of the disease (such as rivastigmine, galantamine, and donepezil), the second category focuses on the specific site or physiological factor of the disease. Still, there are attempts to develop new therapies to prevent, defer, slow down the progress, or ameliorate the symptoms of this disease. Spectrophotometric, chromatographic, and electrochemical methods have proven to be sensitive and reliable for the determination of numerous compounds. In this chapter, recent advances in different analysis methods of various Alzheimer's disease drugs are summarized. Finally, this chapter aims to explore the advantages of methods as well as highlight the future perspectives of these methods in assaying Alzheimer drugs in pharmaceutical and biological samples.

Keywords: Alzheimer's disease, Amperometry, Analysis, Donepezil, Galantamine, Gas chromatography, Huperzine A, Liquid chromatography, Memantine, Potentiometry, Rivastigmine, Spectrophotometry, Spectrofluorimetry, Tacrine, Validation, Voltammetry.

INTRODUCTION

Dementia is a brain disorder resulting in significant deterioration of personal,

* **Corresponding author Bengi Uslu:** Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey; Tel: +903122033178; Fax: +903122131081; E-mail: buslu@pharmacy.ankara.edu.tr

social, and professional functions and it is defined as an acquired deficiency of memorial and cognitive processes. Other brain functions affected by this disease can be enumerated as orientation, calculation, learning abilities, cognition, language abilities, judgment, and reasoning. Dementia is not an outcome of normal aging processes; although there are some significant exceptions, dementia is a progressive disorder [1]. The behavioral changes emerged out of dementia are neither conscious nor are they the results of laziness or “letting go” [2].

Most dementias are categorized as neurodegenerative diseases because they emerged out of progressive degeneration and death of nerve cells [3]. Neurodegenerative disorders are the results of abnormal accumulation of non-dissolved proteins in the brain. These proteins are toxic and they have detrimental effects on selective nerve cells. They deteriorate the functions of these cells leading to the death of these cells at the end. Moreover, this abnormal protein accumulation affects synapses between nerve cells. The neural circuits can be cut because the chemical information between cells can not be transferred properly [4].

Alzheimer's disease (AD) is the most widely seen dementia type comprising almost 50-60% of all dementia cases [5, 6]. It has characteristic neuropathological and neurochemical properties. Generally, it is very insidious at the beginning and it advances slowly but consistently across years [2]. AD can also be defined as a heterogeneous disease which is a combination of environmental and genetic factors. The most significant risk factor for AD is age. The environmental risk factors are hypertension, estrogen supplements, smoking, stroke, cardiac diseases, depression, arthritis, and diabetes [6].

AD is characterized by the development of two main lesions, namely amyloid plaques and neurofibrillary tangles (NFTs) [7]. These two lesions resulted in progressive dementia that emerged out of neuronal dysfunction and death of cells at the hippocampus and medial, temporal, and parietal lobes of the brain. The defection at the hippocampus resulted in deterioration of short term memory and affects the daily routines of the patients. Later, the brain cortex and most importantly the areas responsible for linguistic and reasoning functions are influenced. In the end, other parts of the brain are eclipsed together with atrophy and functional losses [8].

The emergence of amyloid plaques is due to their pathological overproduction or as a result of β -amyloid peptide accumulation around neurons because of deteriorated clearance along the blood-brain barrier. The β -amyloid peptides accumulated at the brain are inclined to accumulate first towards soluble pathogenic β -amyloid oligomers and fibrils and then towards insoluble β -amyloid

plaques. The accumulation of β -amyloid plaques at brain arterial walls resulted in cerebral amyloid angiopathy [7]. According to the amyloid cascade hypothesis, which had been proposed at the beginning of the 1990s, the amyloid accumulations at AD resulting from a series of genetic and environmental factors and the neural cell degeneration emerging out of it ultimately leads to dementia [9].

The second significant lesion of AD is neurofibrillary tangles. The NFTs are composed of a protein called tau. Unlike plaques, the number of NFTs and their anatomical location in the brain is significantly related to the strength of dementia. Moreover, it is thought that the presence of NFTs within nerve cells is a strong indication of prospective cell death. Tau protein stabilizes the microtubules necessary for the rapid transfer of microscopic components at neurons from the nerve cell. The damaging microtubules resulted in functional losses of neurons. In AD, tau protein loses its ability to support microtubule stabilization and transforms into NFTs [10].

Since the definition of the AD at the beginning of the twentieth century, the discovery of amyloid plaques and NFTs at post-mortem brains of the patients became the basis for drug development studies for this disease; however, the discovery of drugs for the treatment of AD started with the discovery of the relationship between memory disorders and cholinergic pathways in 1984 [11]. It is understood that the neurons secreting acetylcholine for a long time are the neurons that are affected by AD the most. Acetylcholine (cholinergic) pathways are critically important for normal memory functions [12]. Since the discovery of the significance of acetylcholine for the treatment of AD, several treatments for overcoming the disease have been attempted. While earlier studies attempting to increase acetylcholine levels in the brain directly were not much promising, the methods developed for indirect boosting of acetylcholine levels by reducing its breakdown have some promising results [1]. Acetylcholinesterase (AChE), which is responsible for the hydrolysis of acetylcholine, was focused on to restore the cognitive impairment through rising neurotransmitter levels in the central nervous system [11]. The changes in neurotransmission in AD happens only after a significant level of cellular death. The lack of acetylcholine is not a reason but a result of the disease; therefore the treatments targeting for increasing the level of acetylcholine in the brain are not much effective to change the underlying causes of the disease [1]. In other words, the actual treatments of AD do not target underlying causes of AD but they attempt to cure the symptoms of the disease [1, 7, 12, 13]. Although numerous drugs are entering clinical monitoring processes, treatments curing the disease effectively can not be developed yet. That is why AD has been perceived as a priority for public health today [7].

CHAPTER 5**Targeting Alzheimer's Disorders Through Nanomedicine****Mahima Kaushik^{1,*} and Dhriti Jha²**¹ Cluster Innovation Centre, University of Delhi, Delhi, India² Bhaskaracharya College of Applied Sciences, University of Delhi, Delhi, India

Abstract: Neurodegenerative diseases have been known to exist in the human population for a long time, yet most of them do not have a cure even until now. With the recent surge of nanotechnology and its applications to physiology as nanomedicine, a new hope for a better future has been offered. Nanomedicine has opened up many areas of further research that can lead us to a probable cure for these diseases. This review particularly focuses on Alzheimer's disease (AD), which is a progressive neurodegenerative disorder. AD primarily affects the cerebral cortex in the forebrain and the hippocampus in the midbrain. According to the World Alzheimer's report, there are 46.8 million AD patients worldwide as of 2016 with a high probability of this statistic becoming double in the next two decades. For understanding this crucial situation, studying the pathology of AD, and recent advancements in the treatment of AD, specifically through nanomedicine becomes extremely important. Through this review, we intend to explore all the relevant aspects in relation to nanotechnological advancements for the treatment of Alzheimer's disease.

Keywords: Alzheimer's disease, Drug Delivery System, Lipid-based Nanoparticles, Neurodegenerative diseases, Nanoparticles, Nanomedicine, Neuroinflammation, Polymeric Nanoparticles.

INTRODUCTION

Neurodegenerative diseases (NDs) are defined as a set of diseases that cause structural modifications to the neurons present in the human nervous system resulting in malfunctioning of the neuronal cells. This ultimately leads to a loss of cognitive, sensory and motor abilities. Though NDs have been prevalent in the human population for a long time, the drugs currently in clinical use are only for disease management and play a little-to-no role in disease cure.

* Corresponding author **Mahima Kaushik:** Cluster Innovation Centre, University of Delhi, Delhi, India; Tel: 91-011-276667020; Fax: 91-011-27666706; E-mails: mkaushik@cic.du.ac.in, kaushikmahima2011@gmail.com

Some of the most popular NDs include Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease (PD) and Frontotemporal dementia (FTD). Most of the NDs are caused due to misfolding of essential messenger proteins such as amyloid plaques, transactive response DNA-binding protein 43 (TDP-43), dopamine neurotransmitters and serotonin. AD is caused by an irreversible neuronal loss and vascular toxicity resulting due to extracellular deposition of A β peptide, in the form of senile plaques, and neurofibrillary tangles of phosphorylated tau protein. In PD, there is loss of neurons involved in the dopaminergic pathway and proteinaceous Lewy bodies, which are α -synuclein aggregates present in the central nervous systems (CNS) and peripheral nervous system (PNS) [1, 2]. Both AD and PD are characterized by progressive memory loss, depleting decision -making ability and, degradation of cognitive and sensory perceptions [3 - 6]. A group of disorders showing rigidity, tremors and stature instability are categorized under a clinical syndrome termed as Parkinsonism [7], including PD as one such kind of disorder. ALS is a type of motor neuron degenerative disorder, where there is damage to motor neurons of both the CNS and the PNS. Here, the nervous connections between both cortex-brainstem and spinal cord-muscles are severely affected [8]. Although, aggregation of TDP-43 is thought to be a major cause of ALS, yet the disease pathway has not been clearly understood until now [8]. FTD is another type of neurodegenerative disorder, which is often linked to ALS due to their genetic and neuropathological common links [9]. A patient of FTD shows signs of forgetfulness and altered social behaviour. Language dysfunctionality is also observed in some kinds of dementia [9].

The recent surge in nanomedicine has given new hope as a prospective cure for NDs. The field of nanomedicine involves the use of nanotechnology for designing particles, with sizes ranging in the order of 10^{-9} m (nanometer), which can potentially be used as drugs and in drug delivery systems to inhibit such misfolding and agglomeration. Most diseases occur due to malfunctioning of some biological aspect involved, at a nanoscale [10]. Through nanoparticle-based drugs and delivery systems, there is an attempt to utilise the similarity in size shared between the nanoparticle and the biological molecules, and target the factors that are ultimately resulting in the disease. Due to their small size, nanomaterials display a high surface area to volume ratio. This translates to higher reactivity as the particles offer more surface area for the ligand to interact with, making it a favourable option for transporting drugs to their targets [11]. It is the dynamic and versatile nature of nanoparticle-based drug designing that gives it an edge over traditional medicine. Still, the extent of nanotoxicity caused and the unknown long-term effects of nanoparticle therapy can pose as disadvantages of this approach. Thus, clinical application of nanotechnology as medicine in NDs require exhaustive studies in appropriate models [12].

Major types of nanoparticles (NPs) commonly associated with biomedical research include liposomes, albumin-based, polymeric NPs, microemulsions, metallic NPs like gold, nano-emulsions, iron oxide and quantum dots [13]. Amongst these, polymeric NPs, lipid NPs, micro- and nano-emulsions are majorly involved in designing nanomedical therapies.

This review particularly focuses on AD, which is a progressive neurodegenerative disorder, primarily affecting the cerebral cortex in the forebrain and the Hippocampus in the midbrain [14, 15]. 46.8 million AD patients were reported worldwide in 2016 by world Alzheimer's report, with an expected double in number in the next two decades [16]. AD can be sporadic or familial in nature. The cases of familial AD are far lower than patients of acquired AD (measured 11.3% in the Asian population in 2016) [17]. The genes that are majorly observed as carriers of mutation leading to AD are *APP*, *PSEN1* and *PSEN2* [5, 18]. Although AD is the most common of all the NDs, researchers do not yet completely understand its complex pathophysiology. Through this review, we attempt to explore the major pathways of the disease, the current treatment used for it and the prospective solutions that nanomedicine-directed research has to offer in future.

AD PATHOLOGY AND CURRENT TREATMENT TRENDS

There are many factors that need to be considered in order to find a cure for a disease. A detailed understanding of the disease pathway can serve as a starting point for exploring potential treatments. Understanding AD and its pathology have provided an insightful approach towards designing treatments and drugs for it. AD results majorly due to inter-cell neurofibrillary tangles and intracellular neuritic plaques [19 - 21]. Paired helical filaments (PHF) form the tangles and amyloid aggregation results in these plaques. Two major pathways (Fig. 1) have been suggested as probable disease pathologies for AD: Beta-amyloid ($A\beta$) cascade and Tau pathology. Both $A\beta$ and Tau protein are associated with normal neuronal metabolism. $A\beta$ is processed through a complex enzyme using amyloid precursor protein (APP) and is cleaved into peptides of various sizes [22, 23]. Modification in the proteolytic processing by APP results in aggregation of $A\beta$ in the neuronal synapses, leading to a decline in the signaling efficiency. Even though inter-neuron $A\beta$ deposition is identified as a crucial factor in AD, yet $A\beta$ accumulation may not be the stand-alone cause of AD. It has been reported that even with the presence of $A\beta$ deposits, the subject still did not suffer from AD.

Tau is a major microtubule-associated protein (MAP) present in six molecular isoforms in a mature neuronal cell in the human nervous system. It is majorly responsible for stabilizing the microtubular network in the neuronal cell.

Current Challenges in Alzheimer's Disease

Umar Mushtaq^{1,*}, Amrina Shafi² and Firdous A. Khanday²

¹ Department of Biotechnology, School of life Science, Central University of Kashmir, Ganderbal, Jammu and Kashmir-191201, India

² Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir-190006, India

Abstract: Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disease, the manifestation of which primarily leads to progressive dementia and ultimately results in death. Currently, 5.5 million people are afflicted with this disease in the USA alone while 50 million are suffering from this disease across the world. The disease is recognised by two pathological markers *viz.* senile plaques and neurofibrillary tangles (NFT). About 50% of the population beyond the age group of over 85 years exhibit symptoms of AD since the majority of cases of AD are sporadic or idiopathic and only 5-10 percent cases are genetic. At present, there is no effective treatment for this disease and most of the drug trials used to control or stop the disease have failed as they are directed to target symptoms and not the cause of the disease. The therapeutic agents that are most commonly used for AD include cholinesterase inhibitors (CI), which enhance cholinergic neurotransmission. Diagnosis of AD still poses a significant challenge regarding the lack of information about the manifestation as well as the status *viz.* progression of this disease. However, there is enough optimism to believe that we will soon be able to develop biomarkers which would help us to accurately detect the progression of the disease. Therefore, the present chapter will provide an extensive overview of the disease and focus on possible ways to develop and formulate effective strategies to control this dreadful disease. The purpose of this citation is to guide researchers and personnel associated with pharmaceutical sciences into a new domain of investigations. This paper depicts the present scenario and projects the future challenges posed by Alzheimer's disease.

Keywords: Alzheimer's disease, Alpha Secretase, Amyloid precursor protein, Beta amyloid, Beta Secretase Biomarkers, cholinesterase, Gamma Secretase, INNOTEST, Neurofibrillary tangle, Neurogranin, Tau.

INTRODUCTION

Alzheimer's disease (AD) is the most common neurological disorder in which the

* Corresponding author Umar Mushtaq: Department of Biotechnology, School of life Science, Central University of Kashmir, Ganderbal, Jammu and Kashmir-191201, India; Tel: 9797396411; E-mail: umar6403@gmail.com

death of neuronal cells leads to dementia and eventually results in fatality [1]. The disease was first described by a German psychiatrist, Alois Alzheimer, in 1906, when he carried out the autopsy of the brain of a patient named Auguste Deter. He found two prominent pathological markers, which were later named as neurofibrillary tangles and neurotic plaques. Neurofibrillary tangles are composed of hyperphosphorylated tau protein and neurotic plaques are composed of beta amyloid peptides [2, 3]. AD as the leading cause of dementia is now reaching an epidemic level in which 5.5 million people in the USA and 50 million people all around the world are suffering from this disease [4]. AD starts in the midbrain with mild cognitive impairment and damages the formation of new memory [5, 6]. The disease then progresses to other parts of the brain which results in problems with speech, mood swings, personality disorders, decision making, and emotions. At later stages of the disease, old memories are also destroyed and the patient becomes completely dependent on care and remains bed-ridden [5, 7, 8]. At present, there is not a single drug, which could cure or stop the progression of this disease [9]. The reason being the pathology of the disease, which starts 20-30 years prior to the appearance of symptoms in the patients and most of the drug trials are used to target symptoms and not the cause of this disease. To stop the progression of the disease at an early stage, researchers in Colombia are targeting the people prone to the early onset of AD due to rare genetic mutations. If researchers are able to develop a drug that could prevent cognitive decline in these individuals, it could revolutionize the drug therapy for this disease. To decrease the symptoms of AD, few drugs are approved by FDA, which target cholinesterase [10, 11] and N-methyl-D-Aspartate (NMDA) glutamate receptor [12]. This is not the only hurdle in the way to find a cure for this disease. AD cannot be diagnosed by a single test. INNOTEST assay, which detects total tau, phosphorylated tau, and beta amyloid 1-42 in cerebrospinal fluid (CSF) was developed 10-15 years ago [13 - 15]. Since then there have been many modifications and advances in the diagnosis of this disease. Novel Ultrasensitive Immunoassay and Mass Spectrometry are holding great promises for early diagnosis of this disease. Efforts are being made for better biomarkers which could detect the exact progression of this disease. One of the recent additions to this group is neurogranin, this protein specifically detects cognitive deterioration in AD [16]. For neurological disorders, including AD, CSF acts as an efficient matrix for biomarkers as compared to the blood. It has an advantage, which is in close proximity to the brain and the brain secretes proteins into it.

PATHOLOGY

In order to develop effective therapeutic drugs to control or stop the progression of this threatening disease, it is imperative to obtain a better understanding of this disease. The disease is caused by abnormal folding and processing of proteins.

AD is recognised by beta amyloid plaques ($A\beta$), neurofibrillary tangles, dystrophic neuritis, and neuropil threads [2, 3]. $A\beta$ plaques are composites of 39 to 43-amino acid peptides generated by sequentially proteolytic cleavage of 110-130 kDa amyloid precursor protein (APP) by beta-secretase (β -secretase) and gamma-secretase (γ -secretase) via the amyloidogenic pathway. In fact, APP is processed *via* two distinct pathways: the amyloidogenic and the non-amyloidogenic pathway. In the non-amyloidogenic pathway, alpha-secretase (α -secretase) cleaves APP, twelve amino acids from the transmembrane domain at the N-terminal, releasing a large soluble fragment known as soluble amyloid precursor protein alpha (sAPP α). The remaining membrane-bound C-terminal fragment of 83 amino-acids called C-terminal fragment alpha (CTF α) is then processed by γ -secretase to liberate the short p3 fragment and the APP intracellular domain (AICD). The amyloidogenic pathway starts with the cleavage of 16 amino acids by β -secretase upstream from the α -secretase cleavage site, generating a soluble amino terminal APP derivative called soluble amyloid precursor protein beta (sAPP β) and a membrane inserted C-terminal fragment beta (CTF β) which is 99 amino acids long. This is followed by further cleavage of CTF β fragment in a progressive manner by γ -secretase, giving rise to $A\beta$ peptides of different lengths from 38–43 amino acids and an additional ACID fragment [17].

Fig. (1) Amyloid plaques which are spherical protein aggregates can be divided into two types: neuritic and diffuse plaques. Neuritic plaques consist of microscopic foci of extracellular filamentous $A\beta$ protein that exhibit a cross-sectional diameter ranging from 10 μ m to 120 μ m. Dystrophic neurites contain enlarged lysosomes, degenerating mitochondria, and paired helical filaments in the vicinity of the plaques along with microglia and astrocytes [18]. The most common isoforms of $A\beta$ are $A\beta$ 40 and $A\beta$ 42; the shorter form is typically produced by cleavage that occurs in the endoplasmic reticulum, while the longer form is produced by cleavage in the trans-Golgi network [19]. The biological functions of APP and the factor(s) that trigger the APP proteolytic cascade remain unclear. The importance of APP in the pathogenesis of Alzheimer's disease is suggested by several findings. Notably, mutations in APP or presenilin; two proteins that are implicated in familial forms of Alzheimer's disease leading to an increase in the amyloidogenic form of $A\beta$ [3]. γ -secretase is an enzyme complex consisting of at least four subunits: presenilin (PS, PS1, or PS2), presenilin enhancer-2 (PEN-2), nicastrin, and anterior pharynx-defective-1 (APH-1). Presenilins 1 and 2 (PS1 and PS2) are highly homologous polytopic membrane proteins of mammals principally localized to the ER and Golgi apparatus [20]. It is the presenilin subunit that possesses the γ -secretase active site responsible for executing the intra-membrane sequential processing of APP [21]. More than 50 miss sense mutations in PS1 and PS2 have been found in families with early-onset Alzheimer's disease and cellular and transgenic modelling of such mutations

Metals Linked to Alzheimer's Disease

Hani Nasser Abdelhamid^{1,*}

¹ *Advanced Multifunctional Materials Laboratory, Department of Chemistry, Assiut University, Assiut 71516, Egypt*

Abstract: Exposure to metals including copper, zinc, aluminum, and iron ions occurs inevitably. Any disturbance in metal homeostasis develops diseases and abnormalities. Metal ions undergo an electric charge balance *via* gaining or losing electrons from surrounded biomolecules. They bind to amyloid fibrils or tau proteins in the brain in a way that links to the development of neurodegenerative diseases including Alzheimer's disease (AD). For several decades, scientists have been exploring possible links between metals imbalance and AD. However, very little is known about the exact mechanisms governing the links of metals to AD. This book chapter summarizes recent thoughts in the research studies that focus on the links between metals and AD. Most of the current results suggested that metal binding to amyloid binds affects the architecture of the protein fibrils and rate of propagation.

Keywords: Alzheimer's disease, Bioinorganic, Metals, Neurodegenerative diseases.

INTRODUCTION

Dementia, including Alzheimer's disease (AD), is a syndrome in which there is deterioration in memory, learning functions, and performance of normal activities [1, 2]. Alzheimer's disease (AD) is a progressive, and chronic neurodegenerative disorder of the brain [1]. According to WHO, it is considered as the most common (60–70%) cause of dementia in elderly people age over 65 years old [1]. It was estimated that 5.3 million people were living with AD, and the patient's number will rise to 13.8 million by 2050. In 2019, the direct costs of caring for people with AD and other dementias are estimated to be \$233.9 billion [3]. Patient of AD at the early stage of dementia suffer from forgetfulness, losing track of the time, and becoming lost in familiar places. These symptoms are progressed to becoming unaware of the time and place, and having difficulty recognizing relatives and friends. Several factors such as mutations in the β -amyloid ($A\beta$) rel-

* **Corresponding author Hani Nasser Abdelhamid:** Advanced Multifunctional Materials Laboratory, Department of Chemistry, Assiut University, Assiut 71516, Egypt; Tel: +20102995242; E-mails: hany.abdelhamid@aun.edu.eg and chemist.hani@yahoo.com

ated genes amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) (<1% of total AD cases), diabetes, hypertension, sleep disorder, and psychological stress may increase the risk of AD [4].

Despite decades of research, scientists still don't fully understand what causes the neurodegenerative disease, although metals are expected to play a significant role in dementia [5]. Metals are ubiquitous and can be found in our daily nutrition [6]. Modern fields such as metallobiology are punctuated by diseases that have specific abnormalities in metals or metal transport proteins, such as acrodermatitis enteropathica (failure of zinc absorption across the intestine) [7], amyotrophic lateral sclerosis (ALS, where Cu/Zn superoxide dismutase 1 plays a role) [8], and Wilson's disease (mutations in the copper transport gene, adenosine triphosphatase ATPase, *ATP7B*) [9]. The links between metals imbalance and neurodegenerative disorders including AD are unknown. Several endogenous proteins are involved in metal transportation on body [10]. The interactions of metal ions with amyloid precursor protein (APP), and A β enhance reactive oxygen species (ROS) formation, leading to A β over-production, aggregation, and enhanced neurotoxicity [11].

This book chapter summarizes the links between metals and Alzheimer's disease [12 - 14]. Different metals such as copper, iron, zinc, magnesium, calcium [15], aluminum [15], magnesium [16], and selenium [17], showed a link to AD [18]. These metals can be essential biometals (*e.g.*, iron, zinc, copper, manganese, magnesium, and calcium), or neurotoxic metals (*e.g.*, aluminum, lead, cadmium, and mercury) [11, 19].

KEY PROTEINS IN THE BRAIN

A β and tau are two key proteins in the brain. Misfolding and aggregation of A β or tau proteins leading to the formation of plaques, and neurofibrillary tangles (NFTs), respectively.

The predominant A β peptide isoforms comprise 40–42 amino acids chains (sequence: AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) [20, 21]. Amyloid is misfolding, and aggregation of amyloid monomers with ordered and stabled structures [22]. Amyloids are typically hard, and waxy deposits consisting of protein. Normally, these folded proteins are cleared from the brain. In contrast, those who suffer from Alzheimer's disease have an unusual amount of sticky amyloid fibrils in their brains. Due to ageing, these fibrils accumulate instead of decomposition, and increasingly hamper functions of the brain.

Tau proteins (τ -proteins) are abundant proteins in neurons of the central nervous

system. The defect in tau proteins prevents stabilization of microtubules properly causing neurodegenerative diseases such as Alzheimer's disease.

LINKS BETWEEN METALS AND AD

The exposure of human to metals occurs daily. Metals are present naturally in the body and can be provided *via* external sources. They can be classified to biological and non-biological metals (Fig. 1). The links between metals and AD for both metals are summarized in Fig. (1), and discussed in the following sections.




Fig. (1). Overview of human exposure to metals causing AD and their links.

BIOMETALS LINK TO ALZHEIMER'S DISEASE

Calcium and Magnesium

Calcium (Ca), and magnesium (Mg) ions serve as messengers and display role in controlling cellular function, neuronal growth, and signal transmission [23].

Excessive Ca^{2+} in the endoplasmic reticulum (ER) is released *via* type 2 ryanodine receptors (RyanR2) in AD spines due to increase in expression and function of RyanR2 [15]. Store-operated Ca^{2+} entry (nSOC) pathway is disrupted in AD spines due to down regulation of stromal interaction molecule 2 (STIM2) proteins. Because of these Ca^{2+} signaling abnormalities, imbalance in activities of Ca^{2+} -calmodulin dependent kinase II (CaMKII), and Ca^{2+} -dependent phosphatase

SUBJECT INDEX

A

- Abnormalities 42, 43, 171, 193, 213, 214
 behavioral 43
 lysosomal 193
 Abnormal microgliosis 221
 Accumulation 42, 43, 44, 45, 49, 50, 51, 99,
 133, 134, 149, 174, 175, 217, 219
 β -amyloid peptide 133
 intraneuronal 45
 lipid 43
 reducing amyloid beta 99
 Acetic acid 146, 175
 ethylene diamine tetra 175
 Acetonitrile 151, 152
 Acetylacetone 147
 Acetylcholine 80, 88, 91, 93, 94, 134, 169,
 170
 neurons secreting 134
 neurotransmitter 88
 Acetylcholinesterase 88, 134, 135, 136, 150,
 170
 enzyme 150
 Acid 9, 14, 82, 78, 79, 94, 95, 96, 97, 98, 99,
 100, 110, 142, 143, 146, 176, 177, 191,
 192
 alpha lipoic (ALA)78, 94, 95, 110
 ascorbic 97, 191
 docosahexaenoic 99
 eicosapentaenoic 99
 folic 95, 96
 γ -aminobutyric 98
 Glacial acetic 146
 glycolic 177
 lactic 177
 lactic-co-glycolic 177
 linoleic 82
 lipoic 94, 95
 okadaic 192
 phosphatidic (PA)78, 79, 100, 176
 phosphoric 142
 trifluoroacetic 143
 zoledronic 9, 14
 zolendronic 14
 Acidic endosomes 50
 Activities 31, 33, 46, 48, 55, 87, 100, 103,
 106, 108, 112, 174, 220, 223
 electrical 33, 103, 106, 112
 enzymatic 220
 ferroxidase 223
 glutaminase 220
 heat-shock-like chaperone 46
 memory-enhancement 100
 nature-related 108
 neuronal 31, 48
 platelet 87
 selective anti-acetylcholinesterase 174
 synaptic 55
 Adenosine triphosphatase ATPase 214
 AD-like 49, 221
 pathology 221
 tau pathology 49
 Adrenal glands 29
 Age-related cognitive impairment 92
 Alzheimer's disease 5, 79, 81, 84, 92, 94, 109,
 165, 172, 189
 and age-related cognitive impairment 92
 and hip fractures 5
 and vascular dementia 84
 early-onset 189
 mild 94
 preventing 109
 risk of developing 79, 81, 94
 treatment of 165, 172
 Ammonium acetate 141, 142, 144, 145, 146
 AMPK 198
 pathways 198
 signaling pathway 198
 Amyloid plaques 26, 47, 55, 101, 133, 134,
 166, 176, 177, 189
 characteristic causative 177
 mature 55
 Amyloid-precursor protein (APP) 44, 47, 48,
 49, 50, 99, 167, 169, 189, 195, 196, 214,
 216, 218, 219

Amyotrophic lateral sclerosis 166
 Analysis 109, 146, 147, 149
 fluorescence 146
 genetic 109
 quantitative 147
 sensitive 149
 Antibody immunotherapy 173
 Anticholinergic 4
 effects 4
 side effects 4
 Anticholinesterase 100
 Anti-inflammatory 53, 87, 89, 98, 173
 actions 87
 effects 53, 89, 98, 173
 Antioxidant 29, 88, 90, 92, 95, 98, 100, 174,
 191, 216, 219, 221
 activity 90
 capacity 191
 curcumin 95
 effects 88
 enzymes 191, 219
 Anti-thrombotic effects 52
 Apoptosis 171, 192, 220
 APP 49, 50, 51, 189, 195, 217
 -mediated iron export 217
 mRNA 217
 processing 49, 50, 51, 195
 proteolytic cascade 189
 transcription 217
 Aromatherapy 100, 101
 Arthritis 87, 133
 Atherosclerosis 41, 51, 81, 82
 ATP-binding cassette (ABC) 36
 Autophagosome 197, 198
 Autophagy 173, 197, 198, 215, 219
 dysfunction 173
 Ayurvedic medicine 88, 91, 92
 traditional 91

B

Beta-secretase 187, 189, 199
 Biomarkers 187
 inhibitors 199
 Bisphosphonates 9, 13, 16
 therapy 13
 oral 9
 Blocks NMDA receptors 170
 Blood-brain barrier (BBB) 26, 32, 35, 36, 38,
 39, 42, 52, 170, 175, 176, 196

Body, proteinaceous Lewy 166
 Body mass index (BMI) 5
 Bone 4, 5, 6, 8, 14, 16
 cysts 16
 grafting 16
 mineral density (BMD) 4, 5, 6, 8
 protection rationalise medications 14
 Bovine 100, 147
 serum albumin 147
 spongiform encephalopathy 100
 Brain 40, 41, 54, 83, 106, 132, 224
 -computer interface (BCI) 106
 derived neurotrophic factor (BDNF) 83
 disorder 132
 lathosterol levels, decreased 54
 lipid profiles 54
 pathologies 40, 41
 proteins 224
 Brain cholesterol 27, 29, 32, 33, 39, 44, 45,
 53, 54
 catabolism, promoted 53
 concentration 54
 content 29
 homeostasis 27, 44
 metabolism 27, 29, 39, 45, 54
 synthesis 33
 Brain injury 27, 26, 32, 43, 44, 52, 100
 acute 44, 52, 100
 traumatic 26, 43
 Bright light therapy 106

C

Cadmium 96, 220
 -related morbidities 220
 homeostasis 96
 Cancer 81, 87, 95, 98, 99, 223
 breast 99
 prostate 98
 Carbon paste electrode (CPE) 149, 150
 Catalase 191, 220
 Cell death 43, 89, 133, 134, 170, 176, 188,
 190, 197, 217
 apoptotic 197
 neuronal 89, 170, 176, 188, 190
 programmed 217
 prospective 134
 Cell membranes 27, 28, 29, 31, 41, 93, 100
 nerve 100
 neuronal 100

- stabilize nerve 93
 - Central nervous system (CNS) 26, 27, 30, 32, 36, 38, 44, 134, 135, 166, 170, 171
 - Cerebral 88, 112, 134
 - amyloid angiopathy 134
 - atrophy 112
 - blood flow 88
 - Chemiluminescence 148
 - intensity 148
 - system, catalyzed 148
 - Cholesterol 27, 28, 29, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 46, 51, 52, 54, 56
 - biosynthesis 27, 37, 38, 51, 54
 - biosynthetic enzymes 34
 - capability 28
 - homeostasis 27, 28, 29, 33, 39, 42, 43, 46, 56
 - synthesis 32, 33, 34, 35, 38, 40, 41, 42, 52, 54
 - Cholesterol levels 31, 37, 40, 42, 43, 45, 50, 51, 52, 53, 54
 - high 31, 43, 45, 52
 - lowering plasma 52
 - lower serum 51
 - Cholesterol metabolism 26, 27, 32, 34, 41, 44, 46, 52, 53, 221
 - dysregulated 44
 - influence 52
 - Cholinesterase inhibitors 79, 80, 91, 94, 96, 97, 135, 169, 170, 176, 187
 - Cognitive 4, 5, 7, 8, 9, 10, 11, 12, 13, 45, 49, 91, 94, 96, 99, 107, 188
 - deterioration 49, 94, 188
 - impairment 4, 5, 7, 8, 9, 10, 11, 12, 13, 45, 91, 94, 96, 99, 107
 - Cognitive function 32, 84, 85, 97, 101, 103, 104, 105, 106
 - global 84
 - Colorimetric 148
 - analysis 148
 - assay 148
 - tests 148
 - Commercial phosphatidylserine products 100
 - Computerized cognitive training (CCT) 105
 - Copper transporter 216
 - Cranial nervous tissue 171
 - CRISPR/Cas9 gene editing technology 48
 - Cyclic voltammetry (CV) 149
 - Cytochrome oxidase enzyme 216
 - Cytokines 91, 102, 171, 190
 - proinflammatory 102
 - pro-inflammatory 91, 190
- ## D
- Damages 166, 170, 188, 191, 192
 - brain cell 170
 - molecular 191
 - oxidative 192
 - Deficiency 5, 8, 13, 55, 91, 110, 133, 222
 - acquired 133
 - thiamine 91
 - Deficits 31, 32, 41, 42, 44, 48, 49, 56, 94, 222
 - abolished cognitive 49
 - exacerbates cholesterol 41
 - in cholesterol synthesis 42
 - neurological 44
 - visuospatial 94
 - Degeneration 133, 134, 171, 216
 - neural cell 134
 - progressive 133
 - Dehydroevodiamine 92
 - Delirium 1, 3, 4, 6, 7, 10, 11, 12
 - perioperative 10
 - Dementia 12, 16, 98, 133, 187
 - mild 12
 - mild-to-moderate 12, 16
 - moderate 12
 - multi-infarct 98
 - progressive 133, 187
 - Dendrimers 173, 174
 - Dendritic spine 31
 - Desmosterolosis 42
 - Diabetic neuropathy 94
 - Dietary 53, 222
 - phytates 222
 - regime 53
 - Dietary restriction (DR) 27, 52, 53, 54
 - on Cholesterol 53
 - Differential pulse voltammetry (DPV) 149, 150, 151
 - Disease 4, 26, 27, 29, 41, 42, 81, 82, 95, 99, 100, 132, 134, 136, 165, 166, 167, 179, 187, 188, 193, 194, 195, 198, 199, 223
 - cardiac 133
 - cardiovascular 26, 95
 - cerebrovascular 82, 100
 - heart 99
 - hereditary 29
 - kidney 81

mild 4
 moderate 4
 neuro-degenerative 27
 neurological 179
 pulmonary 136
 Disorders 8, 29, 42, 85, 86, 87, 101, 102, 103,
 107, 166, 173, 180, 188
 cognitive 86
 degenerative 166
 degenerative neurologic 102
 digestive 87
 neurological 8, 29, 173, 188
 neuropsychiatric 101
 psychiatric 103
 DNA methylation 96
 Drug delivery system (DDS) 165, 166, 171,
 175, 177, 178, 179
 Drugs 4, 8, 26, 80, 91, 132, 134, 135, 136,
 137, 139, 140, 146, 148, 149, 150, 152,
 169, 170, 176, 177, 188, 195, 199, 221
 analysis of 137, 140, 148
 anti-inflammatory 91, 221
 assaying Alzheimer 132
 cardiometabolic 8
 cholesterol-lowering 26
 disease modifying 136
 effective therapeutic 188
 electroactive 148
 Dynein motor proteins 198
 Dysbiosis 102
 Dysfunctions 3, 42, 133, 171, 173, 198, 218
 autonomic 3
 neuronal 42, 133, 198
 Dystrophic neurites 189

E

Ectopic dendrites 42
 Efficiency 93, 151, 175, 177, 178, 197
 encapsulation 177
 higher drug transport 178
 Efficient NP delivery systems 175
 Electroanalytical methods 148
 Electrochemical 140, 148
 detector 140
 techniques 148
 Electrodes 149, 150
 bare glassy carbon 149
 carbon-based 149
 carbon paste 149

 gold 150
 Electroencephalography 78
 Electromagnetic radiation 146
 Endocytosis 30, 37
 rapid 30
 slow 30
 vesicle 30
 Enzyme 33, 34, 38, 39, 41, 88, 91, 94, 95,
 174, 189, 196, 199, 218, 219
 7-dehydrocholesterol reductase 41
 cofactors, essential 95
 superoxide dismutase 174
 Epigalantamine 144
 Epigallocatechin gallate 89
 Estrogen 29, 79, 91, 99
 sex hormones 29
 Exercise 78, 79, 83, 84, 105, 108, 109, 110
 physical 83, 105
 regular 83, 84, 108, 109, 110
 Exposure 4, 5, 54, 104, 213, 215
 regular 104
 sunlight 5
 Expression 38, 46, 87, 172, 178, 190, 194,
 215, 220
 cytokine 190
 enhancing gene 87
 inhibiting ABCA1 46
 iron-binding proteins 220
 symptomatic 172
 Extracellular filamentous A β protein 189
 Extracts of saffron 88

F

Factors 6, 13, 16, 26, 44, 45, 55, 82, 83, 85,
 91, 92, 109, 133, 166, 167, 169, 170,
 171, 176, 199, 221
 activating 87
 brain-derived neurotrophic 83
 gene 169
 genetic 85, 133
 growth 16, 171, 199
 metabolic 110
 nerve growth 91, 176
 pro-inflammatory 171
 protective 82
 tumor necrosis 92, 221
 Fatty acids 37, 82, 83, 93, 110
 metabolism 37
 Fenton reaction 217

Fish consumption 81, 82, 83, 99
 Flatbed chromatography 141
 Fluids 27, 137, 140, 198, 22
 biological 137, 140
 cerebral 222
 Food and drug administration (FDA) 80, 135,
 137, 169, 175, 179, 188, 195
 Foods 27, 32, 81, 82, 83, 95, 96, 110, 193, 220
 antioxidant-rich 110
 Fracture risk 6, 8, 9
 assessment 8
 Fractures 1, 2, 4, 5, 6, 8, 9, 10, 13, 14, 16
 femoral 16
 fragility 1, 9
 immobilise 16
 osteoporotic 13, 14
 vertebral 13, 14
 Fragment 189
 additional ACID 189
 large soluble 189
 membrane-bound C-terminal 189
 Fragmented sleep 84, 85
 pattern 84

G

Galantamine 147, 151, 178
 determination 147
 hydrobromide (GH) 151, 178
 Gas chromatography (GC) 132, 140, 143, 145
 Genes 37, 39, 42, 46, 48, 167, 178, 198, 199,
 214
 copper transport 214
 expression of 48
 encoding enzymes 37
 Genome-wide association studies (GWASs)
 46
 Glassy carbon electrode (GCE) 149, 150
 Glial activation 37, 43, 44, 221
 cells 37, 43, 44
 chronic 221
 Glucosamine 178
 Glucose dysregulation 223
 Glutamate 52, 170, 188, 220
 excitotoxicity 52
 receptor 188
 Glutamatergic 135, 218
 nerve terminals 218
 over-stimulation 135
 Glutamine synthetase 219, 220

Glutathione 94, 176, 191, 220, 221
 levels 221
 peroxidases 191, 220
 Glycohaemoglobin 14
 Glycosphingolipids 31
 Growth 31, 37, 53, 83, 173, 215, 219
 axonal 37
 cellular 173
 neuronal 53, 215

H

Hallucinations 193
 Hantzsch condensation reaction 146
 Hazard ratio 6, 14
 adjusted 14
 Heart rate variability (HRV) 107
 Hepatic enzymes 87
 Hepatotoxicity 80, 135
 Herb lobeline 92
 Herpes viruses 193
 High-performance 139, 140, 141, 142, 143,
 144, 145, 146, 15
 liquid chromatography (HPLC) 139, 140,
 141, 142, 143, 144, 145, 146, 152
 thin-layer chromatography (HPTLC) 141,
 143
 Hip fracture 6, 9, 11, 12, 12
 fixation 11
 prevention 6, 9
 sustain 12, 13
 Hippocampal neurons 83
 Hippocampus 32, 33, 38, 40, 45, 46, 49, 52,
 53, 54, 83, 133, 165, 167, 193, 194
 anterior 83
 human 40
 neurons 194
 posterior 83
 Homeostasis 27, 29, 37, 52, 175, 224
 autonomous 52
 intracellular biometal 224
 oxidative 175
 Homocysteine 45, 96
 Hormone replacement therapy (HRT) 99
 Hormones 27, 29, 79, 98, 99, 169, 173
 androgenic 98
 steroid 27, 29
 HPLC 139, 140
 system 139
 -UV method 140

Subject Index

HPLC-MS 140, 151
 method 140
 technique 151
Human 141, 142, 143, 145, 150
 plasma 141, 142, 143, 145
 serum 150
Huntington's disease (HD) 26, 29, 42, 101
Hydrophobic peptide 195
Hyperlipidemia 43, 47
 type III 47
Hyper-phosphorylation 193
Hypertension 109, 133, 214

I

Infection 10, 193
 herpes virus 193
 pulmonary 193
 urinary tract 10
Inflammatory 44, 190
 cytokine cascades 190
 responses 44, 190
Inhibition 37, 52, 87, 91, 173, 218, 220
 dependent 173
 feedback 37
Inhibitors 4, 80, 87, 88, 135, 172, 196, 199
 allosteric 196
 first acetylcholinesterase 135
 γ -Secretase 196
 monoamine oxidase 80
 multifunctional A β -deposit 172
 secretase 80
 selective serotonin reuptake 4, 87
 serotonin norepinephrine reuptake 4
Injuries 12, 15, 28, 37, 43, 44, 90
 focal cerebral ischemia/reperfusion 90
 nerve 37
Insomnia 106
Insulin 173
 delivery 173
 nanogel conjugate 173
Insulin resistance 44, 109, 221, 223
 reduced 109
 signaling 221
Iron 97, 101, 102, 175, 213, 214, 217, 218,
 220, 223
 accumulations 217
 chelator 217
 chelators attenuate 217
 concentration 220

Frontiers in Clinical Drug Research - Dementia, Vol. 1 241

deficiency 223
homeostasis 217
ions 213
levels 217, 218
mobilization 217
-regulatory proteins (IRPs) 217
storage 217

J

Japanese traditional healing 91

K

Kandutsch-Russell pathway 41
Key enzymes 33, 38, 53, 195, 220
Kinases 178, 192, 198, 216, 221
 associated 178
 cyclin-dependent 198, 216
 extracellular signal-regulated 221
 glycogen synthase 192, 198, 216
 regulatory 198

L

Lactobacillus acidophilus 102
Lactobacillus casei 102
Lactobacillus fermentum 102
Lactoferrin 217, 218
LDL 37, 39, 46
 -cholesterol level 46
 receptor overexpression 39
 -receptor-related protein 37
Light 146, 147
 absorption 147
 emission 146
 scattered 146
Lipid 30, 31, 37, 38, 41, 44, 46, 48, 87, 217,
 220
 arrangement 31
 bilayer, standard 30
 bilayers 220
 biogenesis 37
 biosynthesis 38
 composition 41
 debris 44
 droplets 44
 homeostasis 48
 peroxidation 87

- peroxides 217
 - transport 46
 - Lipid metabolism 44, 46, 48, 55, 223
 - disturbed 44
 - dysregulated 55
 - genes 46
 - perturbation 48
 - Lipoproteins 32, 35, 36, 47, 55, 192, 218
 - cholesterol-rich 55
 - exogenous 32
 - high-density 36
 - Liposomes 167, 176
 - Liquid chromatography (LC) 132, 139, 140
 - high-performance 139
 - ultra-high performance 140
 - Liver X-receptors (LXR) 38, 39
 - Long-term 99, 216
 - depression (LTD) 216
 - neurotoxic effects 99
 - Low-density lipoprotein (LDL) 37, 45
 - Lower circulating testosterone levels 99
 - Lycopodiaceae species 145
 - Lysosomal dysfunction 173
 - Lysosomes 42, 178, 189, 197
 - enlarged 189
- M**
- Massage 107
 - regular foot 107
 - Therapy 107
 - Mass 140, 188
 - spectrometric detector 140
 - spectrometry 188
 - Materials 16, 17, 139, 146, 148, 197
 - osteoconductive 16
 - waste 197
 - Mechanisms 34, 38, 39, 43, 47, 52, 54, 85, 86, 91, 94, 95, 102, 109, 168, 169, 170, 213, 216
 - cholesterol clearance 43
 - efficient compensatory 38
 - exact 47, 213
 - homeostatic 54
 - inflammatory 43
 - putative 91
 - well-oriented defense 170
 - Medications 3, 4, 6, 7, 8, 9, 14, 79, 87, 99, 110
 - anti-osteoporosis 9
 - multiple oral 14
 - psychotropic 3, 110
 - Medicine 86, 88, 92, 136, 166, 179
 - traditional 136, 166, 179
 - traditional Korean 92
 - traditional Persian 86, 88
 - Meditation 108, 111
 - technique 108
 - Mediterranean diet 81, 82, 84
 - traditional 81
 - Melatonin 106, 110
 - Membrane 31, 192
 - fusion 31
 - lipids 192
 - protein, integral 31
 - Membrane proteins 28, 189
 - homologous polytopic 189
 - Memory 31, 32, 80, 83, 86, 87, 88, 90, 92, 94, 98, 100, 105, 134, 136, 188, 193
 - disorders 134, 136
 - enhancing agent 92
 - improving 105
 - long-term 92
 - old 188
 - restoring 88
 - verbal 87
 - visual 87
 - Memory loss 50, 83, 88, 92, 106, 132, 166, 177, 216
 - age-related 88
 - progressive 166
 - MEND protocol report 110
 - Mental health 85, 92, 99, 112
 - benefits 92
 - problems 85, 99, 112
 - Mental retardation 41
 - Metabolic 109, 217
 - enhancement 109
 - network 217
 - Metabolism 32, 37, 40, 42, 53, 94, 100, 167, 217
 - brain glucose 100
 - intracellular 217
 - normal neuronal 167
 - Metabolites 140, 148, 152, 219
 - intracellular toxic 219
 - Metal(s) 101, 175, 213, 214, 215, 216, 218, 219, 220, 221, 222, 223, 224
 - cadmium 220
 - chelators toxicity 175
 - enzymes interactions 224

homeostasis 213, 215, 223
 ion dyshomeostasis 101
 neurotoxic 214, 216
 toxic 218
 Metallobiology 214
 Metalloproteins 217
 Metallothioneins 218, 223
 Methods 111, 139, 141, 146, 147, 148, 149, 150, 178
 amperometric 150
 chromatographic 139, 141
 developed colorimetric 148
 functional brain-imaging 111
 ionic gelation 178
 spectrofluorimetric 146, 147
 spectroscopic 146
 voltammetric 149
 Microcephalia 42
 Microemulsions 167
 Microglia 171, 189, 190
 phagocytic 171
 Microscopic foci 189
 Microtubular network 167
 Microtubule-associated protein 167, 169, 190
 Mild insomnia 98
 Mindfulness-based stress reduction (MBSR) 108
 Mini-mental state examination (MMSE) 4, 9, 12, 91, 104
 Misfolding 166, 169, 197, 214
 and aggregation of A β 214
 Mitochondria 103, 104, 189, 197, 218, 220
 degenerating 189
 Mitochondrial 96, 197, 215, 217, 219, 223
 dysfunction 197, 215, 219, 223
 function 96
 respiration 217
 Mitogen-activated protein kinase (MAPK) 198, 220
 Molecularly imprinted polymer (MIP) 149
 Monomers 171, 177, 214
 amyloid 214
 metabolite 177
 Mood 80, 84, 85, 87, 103, 104, 106, 107, 109, 188, 193, 194
 depressed 80, 84, 85, 104, 109
 improved 104
 regulation 87
 swings 188, 193, 194
 Motor 3, 43, 165, 166

intact 3
 abilities 165
 neurons 166
 MRI images 89
 mRNAs 178, 217, 220
 protein coding 178
 Multiple sclerosis (MS) 26, 101, 140, 143, 145, 146, 152
 Mutations 42, 167, 169, 188, 189, 197, 213, 214, 219
 rare genetic 188
 Myelination, active 33
 Myelin 31, 217
 sheets 31
 synthesis 217

N

Nanoparticles 148, 149, 165, 166, 167, 170, 171, 172, 173, 175, 176, 177, 178, 179, 218, 219
 best polymeric 177
 gold 149, 172, 173
 lipid-based 165, 176
 molybdenum oxide 148
 multilayered 173
 penicillamine-capped selenium 218, 219
 Natural proteins 173
 Nature 107, 108, 166, 167, 172, 173, 175, 179
 ambiguous 179
 binary 174
 inhibitory 173
 strong oxidizing 175
 versatile 166, 172
 Necrosis, regulated 217
 Neostriatum 42
 Nerve 91, 133, 134, 176
 cells 133, 134
 growth factor (NGF) 91, 176
 Nervous system 165, 166, 167, 216
 human 165, 167
 peripheral 166
 Neural 26, 173
 cells structure 26
 drug uptake enhancers 173
 Neurodegeneration 40, 42, 43, 52, 109, 171, 217, 223
 chronic 43

- Neurodegenerative diseases (NDs) 100, 101, 165, 166, 167, 170, 171, 174, 175, 176, 177, 179, 180, 187, 213, 215
 progressive 187
- Neurodegenerative disorders 39, 41, 44, 91, 93, 94, 96, 132, 133, 165, 166, 167, 168, 213, 214, 217
 chronic 213
 progressive 165, 167
- Neurogenesis 83, 98
- Neuroglia 171
- Neurogranin 187, 188, 194, 195
 levels in CSF 194
- Neurological 42, 84
 assessments 84
 symptoms 42
- Neuronal 30, 49, 190, 191
 adaptation 191
 cell adhesion 30
 cholesterol 49
 nicotinic receptor signaling 190
- Neuronal damage 43, 190, 220
 injury-induced 43
- Neuronal injury 52
 secondary 52
- Neuronal loss 83, 166
 age-related 83
 irreversible 166
- Neuropathogenesis 151
- Neuropathological changes 44, 81, 95
 diffuse 81
 features 44
- Neuropeptides 80
- Neuropil threads 189
- Neuroprotection 174
- Neuroprotective effects 52, 92, 93, 95, 102
- Neuropsychiatric symptoms 93, 105
- Neuropsychological tests, sensitive 103
- Neurotheranostics 179
- Neurotherapy 106
- Neurotoxicity 88, 171, 173
 and drug delivery system 171
 neuroinflammatory responses cause 171
 reducing age-related 88
- Neurotransmission 31, 134, 187
 cholinergic 187
- Neurotransmitter 95, 169, 216
 imbalance 169
 synthesis 95, 216
- Neutral endopeptidase 220
- Niacin 79, 96, 97
 dietary 96
- NMDA antagonist 89, 195
 memantine 89
- NMDA receptors 170, 195
 extra synaptic 170
- Non-herbal natural products 93
- Novel ultrasensitive immunoassay 188
- Nuclear 42, 198
 inclusions 42
 receptor binding factor 198
- Nutraceuticals 86, 95
 multiple 95
 single 95
 result 95
- Nutritional strategies 109
- ## O
- Oil, olive 82
- Oligomerization 151, 197
- Orthostatic hypotension 4
- Osteoporosis 1, 7, 8, 9, 13, 14, 16
 management of 7, 13, 14
 treatment of 8, 9, 13
- Osteoporotic hips 16
- Oxidative stress 43, 81, 82, 169, 170, 174, 190, 191, 192, 220, 221, 223
 reactions 223
- Oxysterols 27, 31, 38, 39, 43, 52
 active oxidized products 31
- ## P
- Pain 10, 12
- Pancreatitis 87
- Parkinsonism 166
- Parkinson's disease (PD) 26, 43, 101, 151, 166
- Passive immunotherapies 199
- Pathology 43, 49, 170
 amyloid 49
 beta-amyloid 170
 parkinsonian 43
- Pathways 34, 38, 41, 42, 49, 50, 54, 102, 134, 166, 167, 168, 169, 170, 171, 173, 178, 179, 189, 192, 195, 197, 198, 199, 215, 216, 220
 amyloidogenic 49, 168, 189, 220

cholesterol biosynthetic 42, 54
 cholinergic 134
 cholinesterase 170
 dopaminergic 166
 hormone regulation 168
 inhibiting SREBP 38
 intranasal 178
 metabolic 41, 102, 197
 mitochondrial apoptotic signaling 220
 nonamyloidogenic 189
 non-amyloidogenic 50, 168, 189
 PEGylated liposomes 176
 Peptides 133, 151, 167, 175, 176, 188, 189,
 192
 43-amino acid 189
 amyloid 188
 β -amyloid 133, 151
 Peptidomimetic strategy 196
 Peripheral nervous system (PNS) 166
 Permeability 27, 28, 29, 31, 102, 216
 increased 102
 membrane Ca 216
 reduced 31
 regulating ion 29
 Peroxidase mimetics 148
 Phenotype 47, 48
 neuroinflammatory 48
 protective 47
 Phosphatases 190
 Phosphate buffer 141, 145
 Phosphatidylserine 78, 79, 100
 Phospholipids 31, 36, 100
 phosphatidylserine 100
 Phosphorylation 190, 197, 215, 217, 218
 sequential 190
 Photobiomodulation 79, 103
 Photodiode array detector (PAD) 140, 143,
 145, 146
 Phototoxic reactions 101
 Physical activity 5, 81, 83, 84
 level of 83, 84
 regular 83
 Plaque formation 46, 47, 178, 219
 amyloid 46, 47, 178
 Plaques 44, 46, 134, 166, 167, 176, 177, 188,
 187, 189, 197, 214, 217, 222
 β -amyloid 134
 beta-amyloid 176, 177
 diffuse 189
 neurotic 188

 senile 44, 166, 187, 217, 222
 Plasma 32, 36, 38, 39, 40, 43, 89, 140, 141,
 142, 144, 146, 150, 152
 and vitreous humour 144
 cholesterol 32
 high 43
 concentrations 89
 lipoproteins 32
 Plasma membranes 28, 29, 30, 34, 42
 supply cell 34
 Platelet activating factor (PAF) 86, 87
 Positron emission tomography (PET) 85, 112
 Postural 3, 8, 14
 blood pressure change 8
 hypotension 3, 14
 reflexes 3
 Pressure 10, 11
 sores 11
 ulcers 10
 Preventing 8, 13
 fragility fractures 8
 hip fracture 8, 13
 osteoporosis 8
 Process 27, 28, 29, 30, 31, 32, 33, 34, 36, 37,
 38, 39, 43, 44, 96, 101, 109, 171, 173,
 176, 179, 191, 218
 amyloidogenic 176
 biochemical 191
 biological 96
 cellular 191
 cholinergic 31
 endocytic 218
 inflammatory 43
 injury repair 44
 myelination 33
 pathological 27, 29, 101, 109
 resource-intense 34
 transmembrane signaling 28
 Production 29, 48, 51, 93, 100, 173
 amyloid 48
 β amyloid 51
 hormone 29
 mitochondrial energy 93, 100
 nitrite 173
 Progestagens 99
 Progesterone 29
 Pro-inflammatory macrophages 86
 Proliferation 16, 43, 86
 enhancing neural stem cell 86
 stimulate osteoblast 16

- Propagation 31, 213, 216
 facilitated signal 31
 Properties 4, 88, 95, 133, 136, 148, 171, 216
 antihistamine 4
 anti-inflammatory 136
 antiplatelet 88
 chemical 148
 neurochemical 133
 neuroprotective 95, 216
 Proteases 37, 49, 196
 Proteasomal machinery 38
 Proteasomes 103
 Protein kinases 190, 198, 218, 220, 221
 extracellular regulated 218
 mitogen-activated 198, 220
 Protein production 86, 168
 β -amyloid precursor 86
 Proteins 31, 37, 38, 44, 133, 134, 188, 189,
 190, 194, 195, 196, 197, 198, 214, 215,
 216, 217, 218, 221, 223
 adaptor 198
 associated 196
 endogenous 214
 folded 214
 interacting 198
 intracellular 216
 iron-containing 217
 iron-regulatory 217
 key 44, 214
 non-kinase 198
 proinflammatory 221
 transmembrane 223
 Proteomics 199
 Psychosis 4, 80
 Psychotropics 8
 Pullulan-bearing cholesterol 173
 Purkinje cells 38, 42
 in cerebellum 42
 of cerebellum 38
- R**
- Reactive 87, 103, 170, 174
 gliosis 170
 nitrogen species (RNS) 87, 174
 protein 103
 Reactive oxygen species (ROS) 43, 87, 171,
 174, 190, 191, 192, 214, 216, 217, 218,
 219, 222
 increased 190
- Reagents, chelator 221
 Receptor antagonists 169, 170
 acetylcholine NMDA 169
 function 170
 Receptors 31, 33, 37, 38, 43, 50, 80, 93, 98,
 135, 169, 170, 198, 215, 219
 antagonizing glutamate 80
 brain acetylcholine 93
 dopamine 43
 lipoprotein 33
 melatonin 198
 neurotransmitter 50
 nicotine 169
 postsynaptic glutamate 31
 ryanodine 215
 transient 198, 219
 triggering 198
 Redox homeostasis 174
 Rehabilitation 1, 7, 12, 15, 16, 106
 cognitive 106
 intensive geriatric 16
 intensive inpatient 12
 Relative standard deviation (RSD) 138
 Residues 195, 196
 alanine 195
 aspartate 196
 Resorbable allograft 16
 Retinoid X receptor (RXR) 38
 Reutilization, efficient cholesterol 54
 Risk factors 46, 109, 133
 environmental 133
 important genetic 46
 reducing metabolic 109
 Rivastigmine 80, 132, 135, 140, 141, 142,
 143, 147, 148, 149, 150, 169, 170, 176,
 178
 analysis 147, 148
 determination 140, 147, 148, 149
 free drug 178
 RNA therapy 178
 ROS 174, 191, 217, 221
 reduced 217
 ceasing nanoparticle 174
 levels 191
 scavenging 221
 species 174
 ROS production 48, 190, 191, 192, 197, 215,
 222
 mitochondrial 192

S

- Saffron 88, 89, 90
Salvia miltiorrhiza 86
Salvia officinalis 79, 93
 SCAP N-terminal domain 37
 Scavengers, free-radical 89, 97
 Schwann cells 33
 Selective serotonin reuptake inhibitors (SSRIs) 4, 15, 87
 Selenocysteine 219
 Selenoproteins 221
 Serotonin norepinephrine reuptake inhibitor (SNRI) 4
 Signaling pathways 197, 220, 221
 synaptic calcium 221
 Signals 3, 30, 174
 internal 30
 molecular 174
 Signal transduction 30, 53, 169, 217
 mediated 30
 Sleep 10, 53, 79, 84, 85, 104, 105, 106, 110, 214
 and cognitive function 85
 apnea 85, 110
 disordered breathing 85
 disorders 53, 105, 214
 Smith-Lemli Opitz syndrome (SLOS) 26, 41
 Snoezelen 107
 sessions 107
 therapy 107
 Solid Lipid NPs (SLNs) 176
 Spectrofluorimetry 132, 146, 147, 152
 Spectrophotometric analysis techniques 146
 Square wave voltammetry (SWV) 149, 150
 SREBP-cleavage-activating protein (SCAP) 37, 38
 Stability 34, 111, 175
 emotional 111
 metabolic 34
 Statins 43, 51, 52, 53
 brain-permeable 52
 effects of 43, 52, 53
 expected 52
 first commercial 51
 permeable 52
 popular 51
 Sterol 33, 37
 response element (SRE) 37
 -sensing proteins 33
 Strengthen 16, 17
 bone fragility 16
 osteoporotic bones 17
 Stress 107, 108, 109, 171, 174, 199, 214
 excessive 171
 level 107
 management 109
 nitrosative 174
 psychological 214
 responses 199
 Stroke 81, 86, 97, 99, 108, 133
 risk 86
 Superoxide dismutase 191, 216
 Supplements 86, 96, 97, 99, 100, 102, 109, 110, 221
 copper-containing 102
 daily zinc 102
 dietary 100
 natural 109, 110
 nutrition 221
 omega-3 PUFA 99
 Surgical repair 9, 11, 12
 of hip fracture 11
 Surrogate marker, convenient 39
 Susceptibility 44, 46, 55
 gene 55
 loci 46
 Sustained drug delivery 177
 SWV 149, 150
 serum 150
 techniques for donepezil 149
 Synapses 30, 55, 133, 167, 190, 216
 central 30
 neuronal 167
 Synaptic 26, 30, 31, 48, 91, 170, 194, 218
 extra 170
 cleft 91, 218
 integrity 48
 protein 194
 transmission 26, 30
 vesicle exocytosis 31
 Synaptic plasticity 32, 48, 86, 218
 accelerating 86
 Synaptogenesis 37
 Synaptophysin 31, 48
 Synaptosomes 40
 Synergistic interactions 89
 Synthetic bone grafts 16
 Systems 15, 35, 36, 42, 98, 102, 135, 170, 173, 176, 192, 199, 220, 221

brain lipoprotein 36
 cardiovascular 98
 cellular 192
 cholinergic 220
 complex 102
 endosomal-lysosomal 42
 gastrointestinal 135
 immune 170, 199
 lipoprotein transport 35
 nanogel 173
 neuro 221
 reticuloendothelial 176
 sensor 15

T

- Tacrine 80, 132, 135, 136, 140, 143, 148, 149, 195, 221
 acetylcholinesterase inhibitor 148
 determined 149
 Target 171, 179, 198
 nanoparticle therapy 171
 novel 198
 potential molecular 179
 Tau 50, 52, 167, 168, 169, 187, 188, 190, 191, 192, 193, 194, 195, 196, 198, 218, 220, 223
 ability of 190
 hyperphosphorylated 52
 isoforms of 168, 195
 phosphatases protein phosphates 218
 phosphorylated 50, 188, 194
 reported GSK-3 β phosphorylates 192
 Tau phosphorylation 49, 190, 216, 223
 modulating 49
 Tau proteins 134, 166, 188, 190, 192, 195, 196, 197, 198, 199, 213, 214, 215, 216, 217, 218, 219
 hyperphosphorylated 188, 219
 hyper-phosphorylated 190
 hyperphosphorylation of 192, 198
 phosphor 199
 phosphorylated 166
 Techniques 78, 103, 146, 152, 177
 chemical derivatization 146
 diffusion-evaporation 177
 emulsion polymerization 177
 liquid-liquid extraction 152
 noninvasive 103
 non-invasive brain stimulation 78, 103
 Tetracyclic cholesterol skeleton 27
 Therapies 13, 27, 51, 53, 78, 79, 80, 99, 101, 102, 105, 107, 110, 111, 132, 166, 167, 173, 174, 175, 179, 195
 bone antiresorptive 13
 cognitive 111
 designing nanomedical 167
 energetic 78, 79, 110
 essential oil 101
 estrogen replacement 80, 99
 hormone replacement 99
 iron chelation 102
 metal chelation 175
 multimodal 107
 nanoparticle 166
 nutrition 105
 regular massage 107
 statin 27, 51, 53
 Thiamin-dependent enzymes 96
 Thin-layer chromatography 141
 high-performance 141
 Threonine residues 195
 Tools 8, 15, 98
 fracture risk predictor 8
 reliable diagnostic 98
 use gerontechnology 15
 Toxic 175, 224
 metal exposure 224
 nature results 175
 Transactive response DNA-binding protein 166
 Trans-bilayer translocation 30
 Transcranial 79, 103
 magnetic stimulation (TMS) 79, 103
 ultrasound stimulation 103
 Transcription factors 37, 218
 membrane-bound 37
 Transcriptomics 199
 Transferrin 217
 Transport 32, 35, 42, 53, 143, 176, 192, 219
 altered cholesterol 53
 cellular 143
 enzymes, inactivating 192
 intercellular 35
 lipoprotein 32
 Traumatic brain injury (TBI) 26, 43, 93, 100, 106
 Treatment 1, 13, 52, 91, 99, 107, 132, 134, 135, 136, 137, 165, 169, 170, 172, 177, 178, 179, 217, 221

Subject Index

integrative 107
lithium 217
non-pharmacological 99
Tumor necrosis factor (TNF) 92, 221
Tumour extraction 16
Tyrosine hydroxylase immunoreactivity 43

U

Urinary 12
catheter 12
retention 12

V

Vascular 82, 84, 86, 111, 136, 169
dementia 82, 84, 86, 111
diseases, central 136
hypothesis 169
Vasopressin 80
Visual inspection 138
Visuospatial abilities 99
Visuo-spatial imagery 93
Vitamin 4, 5, 8, 9, 12, 13, 14, 27, 29, 78, 79,
95, 96, 97, 110
biosynthesis of 27, 29
high-dose 97
low 5
soluble 29
supplementation 96
Voltammetry 132, 149, 150
cyclic 149
differential pulse 149, 150
square wave 149
Vomiting 80, 100


W

Water 32, 102, 141, 142, 143, 144, 145, 146,
147, 151
distilled 142, 147
drinking 102
heavy 32
natural 144
Wilson's disease 214, 216

Frontiers in Clinical Drug Research - Dementia, Vol. 1 249

Z

Zinc 97, 101, 102, 175, 213, 214, 218, 219,
222, 223
absorption 214, 218, 222
bioavailability 218
deficiency 223
excessive 218, 223
extracellular 223
oral 102
homeostasis 218
release 218
synaptic 218
Zinc transporters 218
upregulating 218



PROF. DR. ATTA-UR-RAHMAN, FRS

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeichen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.